Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
Active, not recruiting · NCT05654506 · Registry updated 2026-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits | Proliferative Glomerulonephritis With Monoclonal IgG Deposits | Active, not recruiting | Phase 2 | 2026-09-08 | NCT05654506 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic | Rochester | United States | 664 |
| Mayo Clinic | Jacksonville | United States | 122 |
| Oregon Health and Science University | Portland | United States | 382 |
| University North Carolina at Chapel Hill | Chapel Hill | United States | 3 |